This story has been amended to correct errors and remove references to unrelated legal cases.
NEW YORK (GenomeWeb) – A jury has awarded Bio-Rad Laboratories $23.9 million in damages in the firm's patent infringement suit against 10x Genomics, the company announced yesterday.
The Federal District Court jury found that three US patents owned by the University of Chicago and exclusively licensed to Bio-Rad were willfully infringed by 10x. Specifically, the jury unanimously found that all single-cell and linked-read genomics products sold by 10x willfully infringed the patents, according to a statement from Bio-Rad.
In a separate action before the International Trade Commission, an administrative law judge made an initial determination that certain microfluidic devices used by 10x in its products infringe patent rights owned by Bio-Rad, the firm said.
Bio-Rad filed a lawsuit in 2017, claiming infringement on a separate set of seven US patents.
In a statement to GenomeWeb, a 10x spokesperson said, "We strongly disagree with the verdict. We will immediately file an appeal."